Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby
Exelixis (NASDAQ: EXEL), the biotech once left for dead by quite a few investors, continues its resurgence with another solid quarter of sales of its kidney cancer drug Cabometyx. Of course, the third quarter almost doesn't matter that much since most of the biotech's current valuation is supported by potential future sales as Exelixis hopes to expand drug treatment of first-line kidney cancer as well as liver cancer.
Metric
Q3 2017
Source: Fool.com
Exelixis Inc. Stock
€19.85
-0.350%
Exelixis Inc. is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
As a result the target price of 26 € shows a positive potential of 31.02% compared to the current price of 19.85 € for Exelixis Inc..
